Cite this article
4
Downloads
1
Citations
13
Views
Announcements
Alpha Psychiatry (AP) is published by IMR Press from Volume 26 Issue 1 (2025). Previous articles were published by another publisher under the CC-BY-NC licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement.
Open Access
Original Articles
Metabolic parameters in patients with major depression treated with escitalopram
Onur Okan Demirci1, Nurhan Fistikci2, Eser Sagaltici3, Nesrin Karamustafalioglu4, Abdullah Yildirim5, Mehmet Cem Ilnem2
Show Less
Affiliation
1
Psychiatry, Tatvan State Hospital, Tatvan, Bitlis, Turkey
2
Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey
3
Psychiatry, Bitlis State Hospital, Bitlis, Turkey
4
Department of Psychiatry, Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey
5
Psychiatry Department, YuzuncuYil University Medical Centre, Van, Turkey
Alpha Psychiatry 2016, 17(6),
482–488;
https://doi.org/10.5455/apd.214058
Published:
1 December 2016
Abstract
Objective: The aim of this study is to determine the change in metabolic parameters of patients with major depression treated with escitalopram. Methods: The height, body weight, waist circumference, blood pressure, lipid profile (total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides), fasting blood glucose, thyroid stimulating hormone and Hamilton Depression Scale (HamD) of 41 consecutively selected patients with major depression were measured before treatment and in the third month of treatment, for whom a decision to start treatment with escitalopram was decided. The relationship between treatment and changes in these metabolic parameters were evaluated at the end of this period. Results: The mean age of patients was 30.24±9.96 years. Eleven (27%) patients were male and 30 (73%) were female. Twelve (29.3%) patients were treated with 10 mg/day escitalopram, and 29 patients (70.7%) 20 mg/day. Significant increases were detected in body weight, body mass index, waist circumference and systolic blood pressures of all patients from initiation of treatment to three months. A significant increase was found in the waist circumference of male patients (n=11) after twelve weeks of treatment. Body weight, body mass index, waist circumference, triglycerides, systolic blood pressure were found to be significantly increased after three months of treatment in female patients (n=30) who were treated with escitalopram. HamD scores were found to be significantly decreased after three months in patients treated with escitalopram. Conclusion: Escitalopram caused an increase in especially body weight and waist circumference in patients with major depression. [Anadolu Psikiyatri Derg 2016; 17(6.000): 482-488]
Keywords
major depression
metabolic syndrome
metabolic parameters
selective serotonin reuptake inhibitors
escitalopram

